Article

Isosibiricin inhibits microglial activation by targeting the dopamine D1/D2 receptor-dependent NLRP3/caspase-1 inflammasome pathway

Authors: Yan-hang Wang1, Hai-ning Lv1, Qing-hua Cui2, Peng-fei Tu1, Yong Jiang1, Ke-wu Zeng1
1 State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China
2 School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China
Correspondence to: Yong Jiang: yongjiang@bjmu.edu.cn, Ke-wu Zeng: ZKW@bjmu.edu.cn,
DOI: 10.1038/s41401-019-0296-7
Received: 22 February 2019
Accepted: 6 August 2019
Advance online: 10 September 2019

Abstract

Microglia-mediated neuroinflammation is a crucial risk factor for neurological disorders. Recently, dopamine receptors have been found to be involved in multiple immunopathological processes and considered as valuable therapeutic targets for inflammation-associated neurologic diseases. In this study we investigated the anti-neuroinflammation effect of isosibiricin, a natural coumarin compound isolated from medicinal plant Murraya exotica. We showed that isosibiricin (10−50 μM) dose-dependently inhibited lipopolysaccharide (LPS)-induced BV-2 microglia activation, evidenced by the decreased expression of inflammatory mediators, including nitrite oxide (NO), tumour necrosis factor-α (TNF-α), interleukin-6 (IL-6), interleukin-1β (IL-1β) and interleukin-18 (IL-18). By using transcriptomics coupled with bioinformatics analysis, we revealed that isosibiricin treatment mainly affect dopamine receptor signalling pathway. We further demonstrated that isosibiricin upregulated the expression of dopamine D1/2 receptors in LPS-treated BV-2 cells, resulting in inhibitory effect on nucleotide binding domain-like receptor protein 3 (NLRP3)/caspase-1 inflammasome pathway. Treatment with dopamine D1/2 receptor antagonists SCH 23390 (1 μM) or sultopride (1 μM) could reverse the inhibitory effects of isosibiricin on NLRP3 expression as well as the cleavages of caspase-1 and IL-1β. Collectively, this study demonstrates a promising therapeutic strategy for neuroinflammation by targeting dopamine D1/2 receptors.
Keywords: isosibiricin; natural product; neuroinflammation; dopamine D1/2 receptors; inflammatory mediators; NLRP3 inflammasome pathway

Article Options

Download Citation

Cited times in Scopus